國家衛健委:奧密克戎疫苗進入臨牀階段,完成現有疫苗全程接種和加強針接種效果更好
格隆匯5月27日丨據央視,中國疾控中心免疫規劃首席專家王華慶介紹,新冠病毒奧密克戎變異株使得新冠病毒傳染性強、傳播速度更快、傳播過程隱匿,感染風險在加大。目前新冠病毒疫苗對重症死亡的預防效果依然明確且顯著,而且完成現有疫苗全程接種和加強針接種效果更好。開展奧密克戎株疫苗的研究是在未來期望增加應對新冠病毒的手段。奧密克戎變異株的疫苗雖然進入臨牀試驗,確定其研究結果還需要時間,病毒的進化還有一些不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.